South Korean medical aesthetics company Humedix is poised for record earnings in 2026, driven by rapid adoption of its skin booster Elravie Lituo and a recovery in its filler business supported by export diversification into Russia and Thailand. The forecast, issued by iM Securities on June 8, signals strong supply-chain demand for premium injectables and expanding overseas distribution channels.
Skin Booster Elravie Lituo as Core Growth Driver
According to iM Securities analyst Jang Ho, Elravie Lituo has become Humedix's key growth engine since its launch in November 2025. The product generated KRW 9.6 billion in sales last year, with first-quarter 2026 revenue reaching KRW 6 billion. Annual sales are projected to exceed KRW 35 billion, a 264.6% year-on-year increase. The analyst noted that initial marketing costs are easing, accelerating margin improvement.
Filler Business Recovery and Export Diversification
Humedix's filler segment, which had seen slower growth, is entering a recovery phase. In the domestic market, bundling fillers with Elravie Lituo is boosting sales. Overseas, the company has secured product approvals in Russia and Thailand, marking a strategic shift toward geographic diversification. Jang expects filler revenue recovery to become visible from the second quarter onward.
Record Financial Forecast
For the full year 2026, Humedix is expected to post consolidated revenue of KRW 198.6 billion and operating profit of KRW 48.8 billion, representing year-on-year increases of 16.7% and 15.4% respectively. These would be all-time highs for the company.
Sourcing context
For overseas buyers and distributors, Humedix's expanding filler approvals in Russia and Thailand open new procurement channels for Korean-made injectables. The bundling strategy with Elravie Lituo also suggests potential for combined product orders. Importers should monitor regulatory updates in these markets for certification timelines.
Source: Read the original report | Published: June 08, 2026